Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
Trial Parameters
Brief Summary
To observe the PFS of yttrium \[90Y\] microsphere injection combined with FOLFIRI and bevacizumab in second-line treatment of CRLM.
Eligibility Criteria
Inclusion Criteria: 1. 18 years old≤ age ≤ 75 years old 2. Voluntarily signed informed consent 3. Patients with liver metastases of colorectal cancer, colorectal cancer lesions have resection, liver metastases limited to a single lobe 4. The liver tumor progresses after first-line treatment, and FOLFIRI combined with bevacizumab therapy is planned 5. On the assessment of the clinician, the patient was eligible for yttrium \[90Y\] microspheres injection, and treatment with yttrium \[90Y\] microspheres injection was planned 6. KRAS mutant 7. ECOG PS: 0-1 8. Child Pugh score ≤7 9. Adequate level of organ function：a) Hematology: Neutrophils (ANC) ≥1.5×109/L, hemoglobin (HB) ≥90 g/L, platelets (PLT) ≥75×109/L；b) Liver function: albumin \> 3 g/dL; ALT and AST≤ 5 x ULN; TBIL \< 34.0 μmol/L；c) Renal function: serum creatinine ≤176.8 μmol/L or endogenous creatinine clearance \> 50 mL/min；d) Coagulation function: INR≤1.2. Exclusion Criteria: 1. After liver metastasis was diagnosed, the liver und